WASHINGTON (AP) - The Food and Drug Administration on Friday approved Roche's injectable eye drug Lucentis for a new use in treating a diabetes-related condition that can cause blindness.
The agency cleared the drug for diabetic macular edema, a condition that causes swelling and blurred vision in patients with diabetes. In 2010, 3.9 million adults with diabetes reported vision problems, according to the FDA.
Lucentis is currently marketed for wet, age-related macular degeneration, the leading cause of blindness among the elderly. The drug has been facing new competition in that market from Regeneron Pharmaceutical's Eylea, which is cheaper and can be administered with fewer injections.
Side effects with Lucentis include bleeding around the tissue that lines the eyelids and increased pressure on the eyes.
Lucentis is manufactured by Roche's Genentech unit
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
One Atlanta based law-firm says it has a reward for anyone with answers in an Edgar County Arson.
A new tuition plan for St. Patrick School will extend its in-parish tuition discount to all parishes in the Terre Haute Deanery.
Winter temperatures are here and continuing to drop! Wednesday was slated to be the coldest this year.
It's going to be the coldest night of the year. One thing to keep in mind - when the weather gets this cold, it can be dangerous to you.
A Terre Haute man found not guilty of manslaughter and guilty of battery.The jury handed down the verdict Wednesday afternoon.